{"id":"NCT01577732","sponsor":"GlaxoSmithKline","briefTitle":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","officialTitle":"Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-12-08","primaryCompletion":"2013-04-09","completion":"2013-04-09","firstPosted":"2012-04-16","resultsPosted":"2014-05-05","lastUpdate":"2020-01-21"},"enrollment":321,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Acellular Pertussis","Haemophilus Influenzae Type b","Tetanus","Poliomyelitis","Diphtheria","Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix-IPV+Hib™","otherNames":[]}],"arms":[{"label":"Infanrix-IPV+Hib Group","type":"EXPERIMENTAL"}],"summary":"This study aims to evaluate the safety and reactogenicity of a booster dose of Infanrix-IPV+Hib™ when administered to healthy Vietnamese toddlers at 12 to 24 months of age who were vaccinated previously against diphtheria, tetanus, and pertussis diseases within their first six months of lives.","primaryOutcome":{"measure":"Number of Subjects Reporting Solicited Local Symptoms","timeFrame":"Within the 4-day (Days 0-3) follow up period after vaccination.","effectByArm":[{"arm":"Infanrix-IPV+Hib Group","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":["26337197"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":300},"commonTop":["Loss of appetite","Irritability/fussiness","Fever","Pain","Redness"]}}